Novartis announced it will discontinue the trial for organ rejection in patients receiving a kidney transplant.
The analysis indicated that CF Z533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant.
Both CFZ533 and tacrolimus were used in combination with other immunosuppressive therapies (induction therapy, mycophenolate and corticosteroids). Study of CFZ533 in liver transplant continues, as do studies exploring CFZ 533 as a potential treatment in other conditions, such as hidradenitis suppurativa and Sjögren’s syndrome. Novartis is continuing to review the data from the CIRRUS-1 study. Once complete, results will be shared with the broader scientific community.
340 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.